A randomised study of continuous infusional 5-Fluorouracil (5FU) with or without bolus mitomycin-C in patients with carcinoma of unknown primary origin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63374575

Enrollment

Registered

2002-08-19

Start date

1995-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma of unknown primary origin Cancer Malignant neoplasm without specification of site

Interventions

1. Regimen 1. Protracted Venous Infusion (PVI) 5FU 300 mg/m/day over 24 weeks 2. Regimen 2. PVI 5FU 300 mg/m/day over 24 weeks Mitomycin-C 7 mg/m (total not to exceed 56 mg). Four courses over 24 wee

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histological evidence of carcinoma of unknown primary site 2. Patients evaluable for response 3. Must have bi-dimensionally measurable disease as assessed by chest X-ray or Computed Tomography (CT) scan 4. Disease must be outside previously irradiated areas

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Added 05/08/09: 1. tumour response 2. survival 3. toxicity 4. quality of life (QoL)	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026